vs
Side-by-side financial comparison of CATHAY GENERAL BANCORP (CATY) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $222.8M, roughly 1.6× CATHAY GENERAL BANCORP). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs 28.1%, a 625.3% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs 4.8%). CATHAY GENERAL BANCORP produced more free cash flow last quarter ($363.7M vs $209.9M). Over the past eight quarters, CATHAY GENERAL BANCORP's revenue compounded faster (12.8% CAGR vs 1.5%).
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CATY vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $222.8M | $346.4M |
| Net Profit | $90.5M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | 50.9% | 36.1% |
| Net Margin | 653.4% | 28.1% |
| Revenue YoY | 19.5% | 4.8% |
| Net Profit YoY | 12.9% | — |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $222.8M | $339.0M | ||
| Q3 25 | $210.6M | $327.3M | ||
| Q2 25 | $196.6M | $321.4M | ||
| Q1 25 | $187.8M | $330.6M | ||
| Q4 24 | $186.5M | $348.5M | ||
| Q3 24 | $189.5M | $345.5M | ||
| Q2 24 | $178.5M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $90.5M | $44.7M | ||
| Q3 25 | $77.7M | $38.7M | ||
| Q2 25 | $77.5M | $34.0M | ||
| Q1 25 | $69.5M | $58.0M | ||
| Q4 24 | $80.2M | $37.5M | ||
| Q3 24 | $67.5M | $33.8M | ||
| Q2 24 | $66.8M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 50.9% | 19.9% | ||
| Q3 25 | 44.5% | 17.9% | ||
| Q2 25 | 49.0% | 16.8% | ||
| Q1 25 | 46.1% | 21.6% | ||
| Q4 24 | 46.5% | 16.9% | ||
| Q3 24 | 41.2% | 15.0% | ||
| Q2 24 | 40.7% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 653.4% | 13.2% | ||
| Q3 25 | 36.9% | 11.8% | ||
| Q2 25 | 39.4% | 10.6% | ||
| Q1 25 | 37.0% | 17.5% | ||
| Q4 24 | 587.9% | 10.8% | ||
| Q3 24 | 35.6% | 9.8% | ||
| Q2 24 | 37.4% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $1.33 | $0.95 | ||
| Q3 25 | $1.13 | $0.81 | ||
| Q2 25 | $1.10 | $0.70 | ||
| Q1 25 | $0.98 | $1.17 | ||
| Q4 24 | $1.11 | $0.74 | ||
| Q3 24 | $0.94 | $0.66 | ||
| Q2 24 | $0.92 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.4M |
| Total DebtLower is stronger | $119.1M | $1.2B |
| Stockholders' EquityBook value | $2.9B | $796.3M |
| Total Assets | $24.2B | $2.4B |
| Debt / EquityLower = less leverage | 0.04× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $119.1M | $1.2B | ||
| Q3 25 | $119.1M | $1.2B | ||
| Q2 25 | $119.1M | $1.2B | ||
| Q1 25 | $119.1M | $1.2B | ||
| Q4 24 | $119.1M | — | ||
| Q3 24 | $119.1M | — | ||
| Q2 24 | $119.1M | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $2.9B | $911.5M | ||
| Q3 25 | $2.9B | $849.2M | ||
| Q2 25 | $2.9B | $882.3M | ||
| Q1 25 | $2.9B | $820.8M | ||
| Q4 24 | $2.8B | $906.9M | ||
| Q3 24 | $2.8B | $878.9M | ||
| Q2 24 | $2.8B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $24.2B | $2.5B | ||
| Q3 25 | $24.1B | $2.4B | ||
| Q2 25 | $23.7B | $2.5B | ||
| Q1 25 | $23.2B | $2.5B | ||
| Q4 24 | $23.1B | $2.5B | ||
| Q3 24 | $23.3B | $2.5B | ||
| Q2 24 | $23.2B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.04× | 1.34× | ||
| Q3 25 | 0.04× | 1.44× | ||
| Q2 25 | 0.04× | 1.39× | ||
| Q1 25 | 0.04× | 1.49× | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $368.6M | $293.2M |
| Free Cash FlowOCF − Capex | $363.7M | $209.9M |
| FCF MarginFCF / Revenue | 163.2% | 60.6% |
| Capex IntensityCapex / Revenue | 2.2% | 9.5% |
| Cash ConversionOCF / Net Profit | 4.07× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $672.7M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $368.6M | $93.6M | ||
| Q3 25 | $150.6M | $111.3M | ||
| Q2 25 | $64.0M | $17.4M | ||
| Q1 25 | $99.0M | $116.6M | ||
| Q4 24 | $329.2M | $43.8M | ||
| Q3 24 | $81.2M | $48.8M | ||
| Q2 24 | $72.9M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $363.7M | $87.2M | ||
| Q3 25 | $150.1M | $106.3M | ||
| Q2 25 | $62.7M | $13.6M | ||
| Q1 25 | $96.3M | $100.9M | ||
| Q4 24 | $325.5M | $35.2M | ||
| Q3 24 | $80.0M | $39.4M | ||
| Q2 24 | $72.4M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 163.2% | 25.7% | ||
| Q3 25 | 71.3% | 32.5% | ||
| Q2 25 | 31.9% | 4.2% | ||
| Q1 25 | 51.2% | 30.5% | ||
| Q4 24 | 174.6% | 10.1% | ||
| Q3 24 | 42.2% | 11.4% | ||
| Q2 24 | 40.5% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 2.2% | 1.9% | ||
| Q3 25 | 0.2% | 1.5% | ||
| Q2 25 | 0.6% | 1.2% | ||
| Q1 25 | 1.4% | 4.7% | ||
| Q4 24 | 1.9% | 2.5% | ||
| Q3 24 | 0.6% | 2.7% | ||
| Q2 24 | 0.3% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 4.07× | 2.09× | ||
| Q3 25 | 1.94× | 2.88× | ||
| Q2 25 | 0.83× | 0.51× | ||
| Q1 25 | 1.42× | 2.01× | ||
| Q4 24 | 4.10× | 1.17× | ||
| Q3 24 | 1.20× | 1.44× | ||
| Q2 24 | 1.09× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CATY
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
